PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY

HEXASOL LA

(Oxytetracycline/Flunixin) Injection for Cattle

300 mg/mL OXYTETRACYCLINE (as oxytetracycline dihydrate)
and 20 mg/mL FLUNIXIN (as flunixin meglumine)

For use by or under direction of a registered veterinarian

DESCRIPTION:
HEXASOL LA Injection is a clear, dark amber solution for parenteral administration containing 300 mg oxytetracycline as oxytetracycline dihydrate Ph. Eur and 20 mg flunixin as flunixin meglumine USP, per mL.

INDICATIONS:
Oxytetracycline is a member of the tetracycline family of broad spectrum antibiotics that inhibit protein synthesis in susceptible micro-organisms.
Flunixin meglumine is a relatively potent non-narcotic, non-steroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties.
HEXASOL LA Injection is specifically formulated to provide initial anti-inflammatory activity for 24-36 hours and sustained anti-bacterial activity for 5-6 days following a single administration.
HEXASOL LA Injection is indicated primarily for the treatment of bovine respiratory disease associated with *Mannheimia haemolytica* (Pasteurellosis), where an anti-inflammatory and anti-pyretic effect is required in the 24 hours post treatment.
In addition, a wide range of organisms including *Mannheimia* spp, *Arcanobacterium* (*Corynebacterium*) *pyogenes*, *Staphylococcus aureus* and certain mycoplasmas are known to be sensitive *in vitro* to oxytetracycline.
HEXASOL LA may therefore be of use in the treatment of disease in cattle caused by such organisms where both an anti-inflammatory and anti-pyretic effect is required in the 24 hours post treatment.
Although HEXASOL LA is well tolerated, occasionally a slight local reaction of a transient nature may be observed.

Use as directed by prescribing veterinarian.

DIRECTIONS FOR USE
Restraints:
DO NOT USE in lactating cows or within 30 days of calving where milk or milk products may be used for human consumption.
Treated animals must be clearly identified in such a way that they will maintain their identity during the withholding period.

Contra-Indications:
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding or where there is hypersensitivity to the product.
Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.
It is preferable that prostaglandin-inhibiting drugs are not administered to animals undergoing general anaesthesia until fully recovered.

Precautions:
Use in any animals less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
This product does not contain an antimicrobial preservative. Swab the septum before removing each dose. Use a sterile needle and syringe.
Avoid administration of other NSAIDs concurrently or within 24 hours of this product.
Concurrent use of potentially nephrotoxic drugs should be avoided. The stated dose or duration of treatment should not be exceeded. The use of tetracyclines during the period of tooth and bone development, including late pregnancy, may lead to discolouration of the teeth.
Avoid intra-arterial injection.

DOSAGE AND ADMINISTRATION
Following removal of the first dose, the contents of the vial should be used within 28 days. Discard any unused portion.
Give by deep intramuscular injection in the neck region only.
The recommended dosage is 1 mL per 10 kg bodyweight (equivalent to 30 mg/kg oxytetracycline and 2 mg/kg flunixin). Following intramuscular injection of HEXASOL LA at the recommended dose rate, effective oxytetracycline blood levels persist for 5-6 days.

HEXASOL LA may be of use where both an anti-inflammatory and anti-pyretic effect is required in the 24 hours post treatment.
Additional NSAID therapy may be administered after 24 hours if required.
Volume at any one site should not exceed 10 mL. If concurrent treatment is administered, use a separate injection site.

General Directions:
Any variation by the prescribing veterinarian to the approved dose, frequency, duration, route, disease or target species may result in the need to extend the approved withholding period.

WITHHOLDING PERIODS
MEAT: DO NOT USE less than 28 days before slaughter for human consumption.
MILK: DO NOT USE in lactating cows or within 30 days of calving where milk or milk products may be used for human consumption. Should cows calve earlier than 30 days after treatment, milk could contain residues. This milk must not be used for human consumption, or supplied for processing, for at least 30 days following treatment. This milk must not be fed to bobby calves during this time.

EXPORT SLAUGHTER INTERVAL (ESI): DO NOT USE less than 28 days before slaughter for export. The ESI on this label was correct at the time of label approval. Before using this product, confirm the current ESI from the manufacturer on 1800 665 866 or the APVMA website (www.apvma.gov.au/residues/ESI.shtml).

FIRST AID:
If poisoning occurs, contact a doctor or Poisons Information Centre. Phone *Australia 131 126*.

PRESENTATION:
Multi-dose vials of 50 mL, 100 mL, 250 mL and 500 mL.

FURTHER INFORMATION:
Clinically beneficial anti-inflammatory activity has been demonstrated following the single administration of flunixin in HEXASOL LA. However, additional NSAID therapy may be administered after 24 hours if desired.

Dispose of empty container by wrapping with paper and putting in garbage.

Storage:
Store below 25°C (Air Conditioning). Protect from light.

Norbrook Laboratories Australia Pty Limited
ACN 080 972 596
Unit 7/15- 21 Butler Way, Tullamarine, VIC 3043
Free call: 1800 665 866

APVMA Approval No: 55153 /0308

Norbrook®